H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Invivyd (IVVD) to $10 from $5 and keeps a Buy rating on the shares after the company unveiled the REVOLUTION clinical program for VYD2311, a vaccine-alternative monoclonal antibody for COVID-19 prevention. The firm views the REVOLUTION launch as a “meaningful inflection point” that strengthens Invivyd’s regulatory and commercial narrative.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVVD: